Facebook tracking pixel
S10.AI
ICD-10-CM · N60.19GeneralSystemic

Breast Fibrocystic Disease

Understand breast fibrocystic disease, also known as fibrocystic breast changes, fibrocystic mastopathy, or cystic mastopathy. Learn about diagnosis, symptoms, and treatment options. Find information on clinical documentation and medical coding for fibrocystic breast conditions. This resource provides healthcare professionals with relevant information on breast fibrocystic disease.

Also known as
Fibrocystic Breast ChangesFibrocystic MastopathyCystic Mastopathy
Definition

Non-cancerous breast changes with lumpy or rope-like tissue and sometimes breast pain or nipple discharge.

Clinical signs

Breast lumps, tenderness, pain fluctuating with menstrual cycle, nipple discharge (sometimes).

Common settings

Primary care physician, gynecologist, breast specialist clinic.

Related Codes

ICD-10 Code Families

Complete code families applicable to N60.19

N87.0-N87.9
Noninflammatory disorders of female breast
N10-N16
Inflammatory diseases of breast
R92
Abnormal findings on diagnostic imaging of breast
Code Comparison

When to use each related code

DescriptionWhen to use
Benign breast lumps, cysts, and pain.Code B for cyclical breast pain, tenderness, or palpable lumps/cysts. Exclude if related to pregnancy/lactation.
Breast pain without lumps or other findings.Use for Mastalgia/breast pain NOS when no other specific breast diagnosis applies. Rule out other causes.
Single or multiple breast cysts, fluid-filled sacs.Code when distinct cysts are confirmed by imaging (ultrasound/mammogram). Exclude complex cysts or solid masses.
Documentation

Best-practice checklist

  • Document breast lump characteristics (size, location, mobility).
  • Record patient symptoms (pain, tenderness, nipple discharge).
  • Note cyclical changes related to menstrual cycle.
  • Include imaging results (mammogram, ultrasound findings).
  • Specify if aspiration or biopsy was performed.
Coding & Audit Risks

Common pitfalls to avoid

N60.89 vs. N60.10

Incorrect coding between unspecified fibrocystic changes (N60.89) and solitary cyst (N60.10) based on documentation.

Laterality Documentation

Missing or unclear documentation of laterality (right, left, bilateral) impacting code selection and reimbursement.

Unspecified vs. Specific

Overuse of unspecified codes (N60.89) when documentation supports more specific fibrocystic conditions.

Mitigation

Best-practice tips

  • 01Document FBC symptoms, physical exam, imaging results for ICD-10 N60.10.
  • 02Use consistent terminology: Fibrocystic Breast Changes (ICD-10 N60.10) in clinical notes.
  • 03Correlate FBC diagnosis with patient's age and hormonal status for accurate coding.
  • 04Distinguish FBC from other breast conditions during CDI queries for optimal reimbursement.
  • 05Ensure patient education on FBC management and follow-up for compliant care delivery.
Clinical Decision Support

Step-by-step checklist

  1. 1

    Confirm cyclic breast pain, tenderness, or lumpiness.

  2. 2

    Palpable breast masses: mobile, round, well-defined?

  3. 3

    Document breast density on imaging (mammogram/ultrasound).

  4. 4

    Exclude other breast conditions: malignancy, infection.

Documentation Template

Ready-to-paste narrative

Patient presents with complaints consistent with fibrocystic breast changes, including breast pain, tenderness, and a sensation of lumpiness or thickening in the breast tissue.  Symptoms may be cyclical, fluctuating with the menstrual cycle, and often exacerbated premenstrually.  Physical examination reveals palpable nodularity, described as rope-like or granular, bilaterally.  The patient denies any nipple discharge, skin changes, or family history of breast cancer.  No palpable dominant masses are identified.  Ultrasound of the breasts was performed to evaluate the areas of concern and revealed findings consistent with fibrocystic mastopathy, demonstrating multiple small cysts and areas of increased fibroglandular tissue.  Mammography was considered but deferred due to the patient's age and the benign nature of the ultrasound findings.  Diagnosis of fibrocystic breast disease was established based on clinical presentation, physical exam findings, and imaging results.  Patient education was provided regarding the benign nature of this condition, emphasizing that fibrocystic changes are common and not associated with an increased risk of breast cancer.  Conservative management was recommended, including supportive bra, over-the-counter pain relievers such as ibuprofen or acetaminophen, and lifestyle modifications such as reducing caffeine and salt intake.  The patient was advised to perform regular breast self-exams and to return for follow-up if symptoms worsen or new changes develop.  This documentation supports the medical necessity for the evaluation and management of cystic mastopathy, justifying CPT codes for the breast exam and ultrasound.  ICD-10 code N60.10 is appropriate for this encounter.
FAQs

Common questions and answers

How can I differentiate between fibrocystic breast changes and breast cancer during a clinical breast exam?+

Differentiating fibrocystic breast changes from breast cancer during a clinical breast exam can be challenging due to overlapping symptoms. Fibrocystic changes often present as multiple, mobile, tender, and often bilateral masses that fluctuate with the menstrual cycle. These masses are typically smooth and well-defined. Conversely, breast cancer usually presents as a single, firm, non-tender, fixed, and irregularly shaped mass, often with associated skin changes like dimpling or nipple retraction. While a thorough clinical breast exam is crucial, it's important to remember it's not a definitive diagnostic tool. If any suspicious findings are detected, further investigation with imaging studies like mammography or ultrasound, and potentially biopsy, is essential for accurate diagnosis. Consider implementing a standardized breast exam protocol and documentation process to ensure consistency and thoroughness in your practice. Explore how S10.AI can assist in documenting and tracking patient breast health data for improved clinical decision-making.

What are the evidence-based management strategies for symptomatic fibrocystic mastopathy in premenopausal women?+

Managing symptomatic fibrocystic mastopathy in premenopausal women focuses primarily on alleviating discomfort. Evidence-based strategies include lifestyle modifications such as wearing a supportive bra, limiting caffeine and salt intake, and potentially using over-the-counter pain relievers like ibuprofen or NSAIDs. While the evidence is less conclusive, some women find relief with evening primrose oil or vitamin E supplementation. It's crucial to discuss these options with patients, emphasizing that they may not work for everyone. For severe pain or persistent symptoms, hormonal therapies like oral contraceptives may be considered, but the potential risks and benefits should be carefully evaluated. Learn more about the latest research on managing fibrocystic breast changes and how S10.AI can help you stay updated on current best practices.

When should I refer a patient with cystic mastopathy for a biopsy, and what are the key red flags to watch for?+

While most cases of cystic mastopathy are benign, certain red flags warrant further investigation with a biopsy. Key indicators for referral include a new, rapidly growing mass, a persistent palpable mass that doesn't fluctuate with the menstrual cycle, bloody nipple discharge, skin changes like dimpling or retraction, axillary lymphadenopathy, or a suspicious finding on imaging studies such as mammography or ultrasound. It's crucial to have a low threshold for referral when these red flags are present, even if the patient is young or has no family history of breast cancer. Early detection and diagnosis are essential for optimal patient outcomes. Explore how S10.AI can help streamline your referral process and improve communication with specialists for efficient patient care.

Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.

Coding standard: ICD-10-CM, current FY guidelines.